(15R)-Bimatoprost Acid

IMPURITIES

Product Details

CAT No.# CS-T-06503
Category Impurities
CAS 41639-71-8
Molecular Weight 388.5
Molecular Formula C23H32O5
Stock Status: In-Stock
Purity: >98%
Synonyms: (5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3R)-3-hydroxy-5-phenyl-1-penten-1-eptenoic Acid;7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpent-1-en-1-yl)cyclopentyl)hept-5-enoic acid
Application Notes: (15R)-Bimatoprost Acid is an impurity of the antiglaucoma agent Bimatoprost .(15R)-Bimatoprost Acid is a metabolically stable analog of PGF2a and is a potent agonist for the FP receptor.;Impurity in commercial preparations of Bimatoprost
References: Balapure, A.K. et al.: Biochem. Pharmacol., 38, 2375 (1989); Hellberg, M.R. et al.: J. Ocular Pharmacol. Ther., 19, 97 (2003); Krishna, P.M. et al.: J. Pharm. res., 4, 2381 (2011); Resul, B., et al.: J. Med. Chem., 36, 243 (1993)
Shipping: Free Shipping for worldwide on order above 2000 USD , Extra charges for Dry ice shipment 80$*
COA / MSDS:    View COA    MSDS
The balance used are calibrated with weights traceable to National Standards NIST for accuracy
PEOPLE ALSO SEARCHED FOR: 1. propan-2-yl-5-hydroxy-2-methyl-2-4-(3-nitrophenyl)-6-oxo-1,4,5,5-tetraahydropyridine-3-carboxylate
2. ([13C6]Leu5)-Ghrelin (human) (H-7252.1000)
3. Benidipine D7
4. Lauroside D
5. Triazolam 13C D3
6. Icatibant impurity 1
7. BISPHENOL AF (RING-13C12)
8. 0.1% TFA in Water ULC-MS
9. Metamizole EP Impurity C HCl
10. Silodosin Metabolite D4
11. Brivaracetam Carboxylic acid metabolite [UCB 42145]
12. Terbuthylazine D5
13. tibolone (848)
14. (Z)-Dimethylvinphos
15. Silodosin Metabolite
16. 2-Phenoxymethanesulfonanilide
17. Nimesulide EP Impurity A
18. Acetone HPLC
19. Nandrolone Decanoate EP impurity F
20. N-(4-Bromophenyl)-3-methyl-N-(m-tolyl)aniline


Smileys:
O=C(O)CCC/C=C/CC1C(/C=C/C(O)CCC2=CC=CC=C2)C(O)CC1O



This page contains information about (15R)-Bimatoprost Acid Cas 41639-71-8 and its Impurities.
"Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk."